+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

      Journal of clinical oncology : official journal of the American Society of Clinical Oncology

      Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Phytogenic, administration & dosage, adverse effects, Breast Neoplasms, drug therapy, mortality, pathology, Disease-Free Survival, Drug Administration Schedule, Female, France, epidemiology, Head and Neck Neoplasms, Hemangiosarcoma, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Paclitaxel, Scalp, Skin Neoplasms, Soft Tissue Neoplasms, Time Factors, Treatment Outcome

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma. Thirty patients were entered onto the study from April 2005 through October 2006. Paclitaxel was administered intravenously as a 60-minute infusion at a dose of 80 mg/m(2) on days 1, 8, and 15 of a 4-week cycle. The primary end point was the nonprogression rate after two cycles. The progression-free survival rates after 2 and 4 months were 74% and 45%, respectively. With a median follow-up of 8 months, the median time to progression was 4 months and the median overall survival was 8 months. The progression-free survival rate was similar in patients pretreated with chemotherapy and in chemotherapy-naïve patients (77% v 71%). Three patients with locally advanced breast angiosarcoma presented partial response, which enabled a secondary curative-intent surgery with complete histologic response in two cases. One toxic death occurred as a result of a thrombocytopenia episode. Six patients presented with grade 3 toxicities and one patient presented with a grade 4 toxicity. Anemia and fatigue were the most frequently reported toxicities. Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.

          Related collections

          Author and article information



          Comment on this article